Fight dmd trial results selected for late-breaking presentation at mda clinical & scientific conference

Ifetroban demonstrated significant 5.4% improvement in cardiac function nashville, tenn. , march 19, 2025 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its phase 2 fight dmd clinical trial were selected for a late-breaking presentation at the muscular dystrophy association (mda) clinical & scientific conference in dallas.
CPIX Ratings Summary
CPIX Quant Ranking